CoChat

Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research

Open access
Thibault, Benoît, Ramos-Delgado, Fernanda, Guillermet-Guibert, Julie · 2023 · Cancers

The DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index.

Abstract

Phosphatidylinositol-3-kinase (PI3K) enzymes, producing signaling phosphoinositides at plasma and intracellular membranes, are key in intracellular signaling and vesicular trafficking pathways. PI3K is a family of eight enzymes divided into three classes with various functions in physiology and largely deregulated in cancer. Here, we will review the recent evidence obtained during the last 5 years on the roles of PI3K class I, II and III isoforms in tumor biology and on the anti-tumoral action of PI3K inhibitors in preclinical cancer models. The dependency of tumors to PI3K isoforms is dictated by both genetics and context (e.g., the microenvironment). The understanding of class II/III isoforms in cancer development and progression remains scarce. Nonetheless, the limited available data are consistent and reveal that there is an interdependency between the pathways controlled by all PI3K class members in their role to promote cancer cell proliferation, survival, growth, migration and metabolism. It is unknown whether this feature contributes to partial treatment failure with isoform-selective PI3K inhibitors. Hence, a better understanding of class II/III functions to efficiently inhibit their positive and negative interactions with class I PI3Ks is needed. This research will provide the proof-of-concept to develop combination treatment strategies targeting several PI3K isoforms simultaneously.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15030784

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 3 PI3K cross-regulations and possible class I, II and III PI3Ks combination targeting in cancer. (A). PI3K class I isoform cross-regulations upon inhibition of one isoform. Thick lines = primary inhibition, dashed arrows = subsequent regulations. (B). PI3K cross-regulations among different classes are still poorly understood but based on this knowledge, new therapeutic strategies arise to overcome treatment resistance in cancer. (i) All PI3K classes directly or indirectly regulate mTORC1 activity. Class I PI3Kα, β, γ and δ phosphorylate PIP2 into PIP3 which allow the recruitment of PDK1 to the plasma membrane. PDK1 then activates AKT which subsequently enhances mTORC1 activity. The latter can inhibit PI3K in a negative feedback. Class II PI3K-C2α activates mTORC1 and favors its translocation to the plasma membrane via Raptor association to PIP2 [135,140]. On the contrary, PI3K-C2β produces PI(3,4)P2, allowing the link of 14-3-3 which represses mTORC1 [136]. Loss of PI3K-C2γ is responsible for an mTOR activation [96]. Vps34 allows the amino acid activation of the phospholipase D1 (PLD1) which then translocates to the lysosome and stimulates mTORC1 activity [141] but can also inhibit PDK1 sumoylation which results in less AKT and mTOR activation. (ii) Vps34 regulates autophagy while class I PI3Ks modulate proliferation. Both mechanisms are important for cancer cell survival. (iii) Class III PI3K Vps34 can indirectly modulate PI3Kβ activity by allowing PTEN relocalization to intracellular PI(3)P vesicles whose level is regulated by Vps34 [138]. (iv) Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139]. “ON” means that the protein is activated while “OFF” means it is inactivated or absent. Red inhibition or activation lines correspond to possible combination therapies that could be inhibitory or activatory. Of note, all these pathways were demonstrated in different cell types and contexts; the large significance of these data is currently unknown.
Figure 3 PI3K cross-regulations and possible class I, II and III PI3Ks combination targeting in cancer. (A). PI3K class I isoform cross-regulations upon inhibition of one isoform. Thick lines = primary inhibition, dashed arrows = subsequent regulations. (B). PI3K cross-regulations among different classes are still poorly understood but based on this knowledge, new therapeutic strategies arise to overcome treatment resistance in cancer. (i) All PI3K classes directly or indirectly regulate mTORC1 activity. Class I PI3Kα, β, γ and δ phosphorylate PIP2 into PIP3 which allow the recruitment of PDK1 to the plasma membrane. PDK1 then activates AKT which subsequently enhances mTORC1 activity. The latter can inhibit PI3K in a negative feedback. Class II PI3K-C2α activates mTORC1 and favors its translocation to the plasma membrane via Raptor association to PIP2 [135,140]. On the contrary, PI3K-C2β produces PI(3,4)P2, allowing the link of 14-3-3 which represses mTORC1 [136]. Loss of PI3K-C2γ is responsible for an mTOR activation [96]. Vps34 allows the amino acid activation of the phospholipase D1 (PLD1) which then translocates to the lysosome and stimulates mTORC1 activity [141] but can also inhibit PDK1 sumoylation which results in less AKT and mTOR activation. (ii) Vps34 regulates autophagy while class I PI3Ks modulate proliferation. Both mechanisms are important for cancer cell survival. (iii) Class III PI3K Vps34 can indirectly modulate PI3Kβ activity by allowing PTEN relocalization to intracellular PI(3)P vesicles whose level is regulated by Vps34 [138]. (iv) Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139]. “ON” means that the protein is activated while “OFF” means it is inactivated or absent. Red inhibition or activation lines correspond to possible combination therapies that could be inhibitory or activatory. Of note, all these pathways were demonstrated in different cell types and contexts; the large significance of these data is currently unknown.CC BY · PubMed Central
Figure 1 PI3Ks are divided into 3 classes with different substrates and functions. Class I, II and III PI3Ks catalyze the same biochemical reaction on distinct substrates localized at the plasma membrane or the organelle membrane. Some phosphatases can catalyze the opposite reaction of PI3Ks such as Phosphatase and Tensin homolog (PTEN), myotubularin (MTM) and MTM-related protein (MTMR). Class I is composed of 4 isoforms (PI3Kα, β, δ and γ), class II of 3 isoforms (PI3K-C2α, β and γ) and class III has only one isoform, Vps34. Physiological and pro-tumoral functions of class I PI3Ks are well described while limited information is available on the roles of class II and III PI3Ks in cancer.
Figure 1 PI3Ks are divided into 3 classes with different substrates and functions. Class I, II and III PI3Ks catalyze the same biochemical reaction on distinct substrates localized at the plasma membrane or the organelle membrane. Some phosphatases can catalyze the opposite reaction of PI3Ks such as Phosphatase and Tensin homolog (PTEN), myotubularin (MTM) and MTM-related protein (MTMR). Class I is composed of 4 isoforms (PI3Kα, β, δ and γ), class II of 3 isoforms (PI3K-C2α, β and γ) and class III has only one isoform, Vps34. Physiological and pro-tumoral functions of class I PI3Ks are well described while limited information is available on the roles of class II and III PI3Ks in cancer.CC BY · PubMed Central
Figure 2 Engagement of class I PI3K isoforms in cancer depending on genetic alterations or context-dependent activation. Tumors’ specific dependency on PI3K inhibitors is mainly based on (i) genetic alterations and (ii) context-dependent activation of isoforms. (i) Oncogenic activation of PI3Kα catalytic domain leads to PI3Kα sensitivity while PI3Kβ gene amplification or PTEN loss is responsible for PI3Kβ inhibitors’ efficacy. RAS oncogenic activation directly couples with PI3Kα,γ or δ isoforms (but not PI3Kβ) [49,50]. (ii) GSK3β-dependent inhibitory phosphorylation of PTEN could possibly increase sensitivity to PI3Kα or PI3Kβ inhibitors. Inflammatory context (e.g., TNFα [17], GPCR ligand S1P [43]) activates PI3Kα or PI3Kβ/PI3Kγ, respectively. Mechanical signals possibly promote PI3Kβ activation [40]. Increased expression of PI3Kγ promotes PI3K activation [51].
Figure 2 Engagement of class I PI3K isoforms in cancer depending on genetic alterations or context-dependent activation. Tumors’ specific dependency on PI3K inhibitors is mainly based on (i) genetic alterations and (ii) context-dependent activation of isoforms. (i) Oncogenic activation of PI3Kα catalytic domain leads to PI3Kα sensitivity while PI3Kβ gene amplification or PTEN loss is responsible for PI3Kβ inhibitors’ efficacy. RAS oncogenic activation directly couples with PI3Kα,γ or δ isoforms (but not PI3Kβ) [49,50]. (ii) GSK3β-dependent inhibitory phosphorylation of PTEN could possibly increase sensitivity to PI3Kα or PI3Kβ inhibitors. Inflammatory context (e.g., TNFα [17], GPCR ligand S1P [43]) activates PI3Kα or PI3Kβ/PI3Kγ, respectively. Mechanical signals possibly promote PI3Kβ activation [40]. Increased expression of PI3Kγ promotes PI3K activation [51].CC BY · PubMed Central
Figure 4 Combi/hybrid molecules, annihilating several targets at once. The use of targeted therapies in clinics has highlighted the appearance of frequent treatment resistance due to the activation of compensatory feedbacks, requiring inhibiting several signaling nodes at once. Combi- or hybrid molecules have been developed to overcome these limitations by targeting several biological targets (kinases, DNA, etc.) with one entity, allowing better control of the pharmacokinetics and pharmacodynamics of drug combinations. Currently, there are 3 types of combi/hybrid molecules, depending on their mechanism of action. Type I can block target A as an intact molecule but is required to be hydrolyzed to block A and B; Type II can block targets A and B without being hydrolyzed; Type III can block targets A and B as an intact molecule or after being hydrolyzed. Combi/hybrid molecules are one of the proposed novel therapeutic solutions to target specific PI3K isoforms among the 3 classes, depending on their relative importance in a type of cancer, using only one molecule.
Figure 4 Combi/hybrid molecules, annihilating several targets at once. The use of targeted therapies in clinics has highlighted the appearance of frequent treatment resistance due to the activation of compensatory feedbacks, requiring inhibiting several signaling nodes at once. Combi- or hybrid molecules have been developed to overcome these limitations by targeting several biological targets (kinases, DNA, etc.) with one entity, allowing better control of the pharmacokinetics and pharmacodynamics of drug combinations. Currently, there are 3 types of combi/hybrid molecules, depending on their mechanism of action. Type I can block target A as an intact molecule but is required to be hydrolyzed to block A and B; Type II can block targets A and B without being hydrolyzed; Type III can block targets A and B as an intact molecule or after being hydrolyzed. Combi/hybrid molecules are one of the proposed novel therapeutic solutions to target specific PI3K isoforms among the 3 classes, depending on their relative importance in a type of cancer, using only one molecule.CC BY · PubMed Central
Figure 5 Future direction for PI3K targeting in cancer. Efforts have to be made to improve efficacy of PI3K inhibitors and reduce their toxicity in cancer treatment. Improving efficacy will require better knowledge of PI3K cross-regulations and the role of class II and III in cancer, to target several PI3K isoforms among the 3 classes and to combine existing PI3K inhibitors with classical chemotherapies. Reducing toxicity will go through a better dose management, different schedules of treatment and a better understanding of isoform specificity in organs and in cancer subtypes.
Figure 5 Future direction for PI3K targeting in cancer. Efforts have to be made to improve efficacy of PI3K inhibitors and reduce their toxicity in cancer treatment. Improving efficacy will require better knowledge of PI3K cross-regulations and the role of class II and III in cancer, to target several PI3K isoforms among the 3 classes and to combine existing PI3K inhibitors with classical chemotherapies. Reducing toxicity will go through a better dose management, different schedules of treatment and a better understanding of isoform specificity in organs and in cancer subtypes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 148 references

Cited by

See all 41

Metadata

Authors
Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France
Venue
Cancers
Publisher
MDPI AG
Published
2023-01-27
Volume
15
Issue
3
Pages
784
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4318485540
Cited by
40
References
151
Citations by year
2026: 14 · 2025: 12 · 2024: 12 · 2023: 2
FWCI
1.05
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
Funders
  • ANR JCJC program Radiance (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • MSCA-ITN/ETN PhD-PI3K (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • IUCT-O/ICR translational program (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • Ligue Régionale Contre Le Cancer (2020, 2021) (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • Fondation Arc (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • ANR (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
  • Laboratoire d’Excellence (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
phosphatidylinositol 3-kinase, PI3K inhibitors, isoform-selective inhibitors, cancer therapy, tumor microenvironment, tumor cell proliferation, cancer metabolism, combination therapy, PI3K signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. https://app.cochat.ai/papers/10.3390/cancers15030784
The paper
Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023). Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. Cancers. https://doi.org/10.3390/cancers15030784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.